NASDAQ:MRKR Marker Therapeutics (MRKR) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free MRKR Stock Alerts $4.30 -0.04 (-0.92%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$4.15▼$4.5550-Day Range$3.63▼$4.9152-Week Range$0.67▼$9.68Volume19,774 shsAverage Volume21,260 shsMarket Capitalization$38.27 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Marker Therapeutics alerts: Email Address Marker Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.34% of Float Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment0.48Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.29 out of 5 starsMedical Sector791st out of 938 stocksPharmaceutical Preparations Industry371st out of 441 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Marker Therapeutics. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.34% of the float of Marker Therapeutics has been sold short.Short Interest Ratio / Days to CoverMarker Therapeutics has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Marker Therapeutics has recently decreased by 6.96%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMarker Therapeutics does not currently pay a dividend.Dividend GrowthMarker Therapeutics does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMarker Therapeutics has received a 53.36% net impact score from Upright. Marker Therapeutics seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Marker Therapeutics is -0.75. Previous Next 3.0 News and Social Media Coverage News SentimentMarker Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Marker Therapeutics this week, compared to 1 article on an average week.Search Interest1 people have searched for MRKR on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Marker Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Marker Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.10% of the stock of Marker Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.39% of the stock of Marker Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioMarker Therapeutics has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Marker Therapeutics Stock (NASDAQ:MRKR)Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing MT-401, which is in Phase 2 clinical trial for the treatment of post-transplant AML; MT-401-OTS for the treatment of AML; and MT-601 for the treatment of pancreatic cancer and lymphoma. Marker Therapeutics was founded in 1999 and is headquartered in Houston, Texas.Read More MRKR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRKR Stock News HeadlinesMarch 26, 2024 | msn.comMarker Therapeutics GAAP EPS of -$1.59, revenue of $3.31MMarch 25, 2024 | globenewswire.comMarker Therapeutics Reports Year-End 2023 Corporate and Financial ResultsMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 22, 2024 | globenewswire.comMarker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceMarch 22, 2024 | msn.comJudge Dismisses Lawsuit Over Removal of Marker Dedicated to Communist Party LeaderMarch 14, 2024 | finance.yahoo.comGlobal Marker Pens Market Projected to Reach $492.3 Million by 2030, Driven by a Robust CAGR of 5.2%March 13, 2024 | msn.comEliminate Marker Stains From Brick Surfaces With A Handy Hydrogen Peroxide TrickMarch 12, 2024 | finance.yahoo.comNimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of DirectorsMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.February 16, 2024 | usatoday.comLegislators: Why are women overlooked for Florida's Historical Marker Program?February 3, 2024 | msn.comEXPO Low Odor Dry Erase Marker Starter Set, Now 29% OffJanuary 22, 2024 | finance.yahoo.comMarker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601December 21, 2023 | finance.yahoo.comMarker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”December 12, 2023 | msn.comPSTX, MRKR and GPRO among pre-market losersDecember 11, 2023 | marketwatch.comMarker Therapeutics Shares Rise on Positive MT-601 UpdateDecember 11, 2023 | finance.yahoo.comMarker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T RelapseDecember 4, 2023 | msn.comPICS: Festive style shines at Anantara The Marker Hotel's Christmas tree eventNovember 20, 2023 | msn.comCommunity dedicates Blue/Gold Star Hwy MarkerNovember 15, 2023 | businesswire.comSales Marker Introduces AI Sales to the WorldNovember 10, 2023 | msn.comMarker Therapeutics GAAP EPS of -$0.34, revenue of $257.61MNovember 9, 2023 | morningstar.comMarker Therapeutics Inc MRKRNovember 9, 2023 | finance.yahoo.comMarker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNovember 8, 2023 | msn.comBlue Star Memorial Highway Marker dedication set for Nov. 9 in Wrightsville BeachNovember 4, 2023 | msn.comJackrabbits run past Bison, Marker stays in BrookingsNovember 4, 2023 | msn.comDakota Marker dominance: Jackrabbits cruise over North Dakota StateNovember 4, 2023 | msn.comLive Blog: #1 SDSU hosts #11 NDSU in Dakota Marker matchupNovember 3, 2023 | msn.comNDSU vs SDSU Dakota Marker Rivalry Game Bobbleheads revealedSee More Headlines Receive MRKR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/29/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MRKR CUSIPN/A CIK1094038 Webwww.markertherapeutics.com Phone(713) 400-6400FaxN/AEmployees67Year Founded2018Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,930,000.00 Net Margins-77.33% Pretax Margin-424.10% Return on Equity-98.22% Return on Assets-62.67% Debt Debt-to-Equity RatioN/A Current Ratio5.57 Quick Ratio7.01 Sales & Book Value Annual Sales$3.31 million Price / Sales11.56 Cash FlowN/A Price / Cash FlowN/A Book Value$2.34 per share Price / Book1.84Miscellaneous Outstanding Shares8,900,000Free Float6,747,000Market Cap$38.27 million OptionableNot Optionable Beta1.49 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMs. Elizabeth DonnellyDirector of AdministrationMr. Edmund CheungVice President of Human ResourcesDr. Nadia Agopyan Ph.D.Senior Vice President of Regulatory AffairsDr. Monic Stuart M.D.Chief Medical OfficerMr. Gerald GarrettSenior Vice President of Clinical OperationsDr. Robert Z. Florkiewicz Sr.Senior Director of Molecular Biology & VirologyMore ExecutivesKey CompetitorsDURECTNASDAQ:DRRXVYNE TherapeuticsNASDAQ:VYNECara TherapeuticsNASDAQ:CARAImmunoPrecise AntibodiesNASDAQ:IPAProMIS NeurosciencesNASDAQ:PMNView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 3,975 shares on 3/11/2024Ownership: 2.532%Vanguard Group Inc.Bought 3,975 shares on 2/15/2024Ownership: 2.532%Northern Trust CorpBought 27,830 shares on 2/13/2024Ownership: 0.435%International Assets Investment Management LLCBought 10,000 shares on 1/25/2024Ownership: 0.124%International Assets Investment Management LLCBought 10,000 shares on 1/24/2024Ownership: 0.124%View All Institutional Transactions MRKR Stock Analysis - Frequently Asked Questions How have MRKR shares performed in 2024? Marker Therapeutics' stock was trading at $5.50 at the beginning of the year. Since then, MRKR stock has decreased by 21.8% and is now trading at $4.30. View the best growth stocks for 2024 here. When is Marker Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our MRKR earnings forecast. How were Marker Therapeutics' earnings last quarter? Marker Therapeutics, Inc. (NASDAQ:MRKR) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.01. Marker Therapeutics had a negative trailing twelve-month return on equity of 98.22% and a negative net margin of 77.33%. What other stocks do shareholders of Marker Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Marker Therapeutics investors own include Amarin (AMRN), Viking Therapeutics (VKTX), PhaseBio Pharmaceuticals (PHAS), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Genocea Biosciences (GNCA), Strongbridge Biopharma (SBBP), Flexion Therapeutics (FLXN), Geron (GERN) and Ionis Pharmaceuticals (IONS). Who are Marker Therapeutics' major shareholders? Marker Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.53%), Vanguard Group Inc. (2.53%), Northern Trust Corp (0.44%), International Assets Investment Management LLC (0.12%), International Assets Investment Management LLC (0.12%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Frederick Gerald Wasserman and Norman David Eansor. View institutional ownership trends. How do I buy shares of Marker Therapeutics? Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MRKR) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.